Case Report: An Atypical Form of Familial Partial Lipodystrophy Type 2 Due to Mutation in the Rod Domain of Lamin A/C.


Journal

Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782

Informations de publication

Date de publication:
2021
Historique:
received: 02 03 2021
accepted: 29 03 2021
entrez: 6 5 2021
pubmed: 7 5 2021
medline: 21 12 2021
Statut: epublish

Résumé

Familial partial lipodystrophy type 2 (FPLD2) patients generally develop a wide variety of severe metabolic complications. However, they are not usually affected by primary cardiomyopathy and conduction system disturbances, although a few cases of FPLD2 and cardiomyopathy have been reported in the literature. These were all due to amino-terminal heterozygous lamin A/C mutations, which are considered as new forms of overlapping syndromes. Here we report the identification of a female patient with FPLD2 due to a heterozygous missense variant c.604G>A in the exon 3 of the This report supports the idea that there are "atypical forms" of FPLD2 with cardiomyopathy, especially when a pathogenic variant affects the lamin A/C head or alpha-helical rod domain. It also highlights how increased understanding of the genotype-phenotype correlation could help clinicians to schedule personalized monitoring of the lipodystrophic patient, in order to prevent uncommon but possible devastating manifestations, including arrhythmias and sudden death.

Identifiants

pubmed: 33953703
doi: 10.3389/fendo.2021.675096
pmc: PMC8092436
doi:

Substances chimiques

LMNA protein, human 0
Lamin Type A 0
Lamins 0
lamin C protein, human 0

Types de publication

Case Reports

Langues

eng

Sous-ensembles de citation

IM

Pagination

675096

Informations de copyright

Copyright © 2021 Cecchetti, D’Apice, Morini, Novelli, Pizzi, Pagotto and Gambineri.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer VG declared a shared affiliation with several of the authors, MA, EM, GN, to the handling editor at time of review.

Références

J Card Fail. 2013 Apr;19(4):233-9
pubmed: 23582089
N Engl J Med. 1999 Dec 2;341(23):1715-24
pubmed: 10580070
Diabetol Metab Syndr. 2012 Aug 31;4(1):40
pubmed: 22938045
J Clin Endocrinol Metab. 2013 Jul;98(7):3058-67
pubmed: 23780369
Nucleus. 2018;9(1):543-544
pubmed: 30719953
J Clin Endocrinol Metab. 2001 Jan;86(1):59-65
pubmed: 11231979
Am J Med. 2002 May;112(7):549-55
pubmed: 12015247
Nucleus. 2018 Jan 1;9(1):249-260
pubmed: 29557732
J Clin Endocrinol Metab. 2019 Aug 1;104(8):3068-3076
pubmed: 31194872
Eur Heart J Cardiovasc Imaging. 2015 Mar;16(3):233-70
pubmed: 25712077
Exp Cell Res. 2007 Jun 10;313(10):2121-33
pubmed: 17467691
J Card Fail. 2001 Sep;7(3):249-56
pubmed: 11561226
Heart. 2018 Mar;104(6):468-479
pubmed: 29175975
J Cardiovasc Magn Reson. 2009 Mar 03;11:5
pubmed: 19257889
Clin Genet. 2010 Jul;78(1):66-73
pubmed: 20041886
Clin Genet. 2005 Jul;68(1):31-4
pubmed: 15952983
Annu Rev Biochem. 2004;73:749-89
pubmed: 15189158
J Investig Med High Impact Case Rep. 2016 Jul 15;4(3):2324709616658495
pubmed: 27504462
Lancet Diabetes Endocrinol. 2014 May;2(5):396-405
pubmed: 24795253
Mol Genet Metab. 2000 Dec;71(4):539-44
pubmed: 11136544
Endocrinol Metab Clin North Am. 2016 Dec;45(4):783-797
pubmed: 27823605
Diabetes Metab Syndr Obes. 2020 May 06;13:1531-1544
pubmed: 32440182
Clin Genet. 2006 Oct;70(4):261-74
pubmed: 16965317
Clin Chem. 1972 Jun;18(6):499-502
pubmed: 4337382
J Clin Endocrinol Metab. 2004 Nov;89(11):5337-46
pubmed: 15531479
J Endocrinol Invest. 2019 Jan;42(1):61-73
pubmed: 29704234
Trends Mol Med. 2003 Sep;9(9):370-5
pubmed: 13129702
Genet Med. 2020 Sep;22(9):1478-1488
pubmed: 32528171
J Clin Endocrinol Metab. 2016 Dec;101(12):4500-4511
pubmed: 27710244
Acta Myol. 2013 May;32(1):7-17
pubmed: 23853504
Clin Genet. 2007 Jun;71(6):592-3; author reply 594-6
pubmed: 17539910
Clin Endocrinol (Oxf). 2021 Jan 27;:
pubmed: 33502018
Diabetes Metab. 2019 Sep;45(4):382-389
pubmed: 30287275
Diabetes Care. 1998 Dec;21(12):2191-2
pubmed: 9839117

Auteurs

Carolina Cecchetti (C)

Division of Endocrinology and Diabetes Prevention and Care, Department of Medical and Surgical Sciences (DIMEC), Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

M Rosaria D'Apice (MR)

Laboratory of Medical Genetics, Tor Vergata Hospital, Rome, Italy.

Elena Morini (E)

Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, Italy.

Giuseppe Novelli (G)

Laboratory of Medical Genetics, Tor Vergata Hospital, Rome, Italy.
Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, Italy.

Carmine Pizzi (C)

Unit of Cardiology, Department of Specialistic, Diagnostic and Experimental Medicine, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

Uberto Pagotto (U)

Division of Endocrinology and Diabetes Prevention and Care, Department of Medical and Surgical Sciences (DIMEC), Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

Alessandra Gambineri (A)

Division of Endocrinology and Diabetes Prevention and Care, Department of Medical and Surgical Sciences (DIMEC), Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH